AtriCure and SNDL are both small-cap medical companies analyzed for investment potential. Analysts favor SNDL due to its higher potential upside.
AtriCure (NASDAQ: ATRC) has a consensus target price of $48.43, indicating a potential upside of 71.07%. In contrast, SNDL (NASDAQ: SNDL) has a consensus target price of $5.00, suggesting a potential upside of 275.94%. Analysts believe SNDL is more favorable due to its higher possible upside. AtriCure has a beta of 1.43, indicating greater volatility compared to the S&P 500, while SNDL has a beta of 0.81, suggesting lower volatility.